BamSEC and AlphaSense Join Forces
Learn More

Zentalis Pharmaceuticals Inc. – Material Contracts

NASDAQ: ZNTL    
Share price (3/27/26): $2.10    
Market cap (3/27/26): $149 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.14
from 10-K 24 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Information the Registrant Customarily and Actually Treats as Private or Confidential and Is Not Material. Employment Agreement
12/34/56
EX-10.1
from 10-Q 15 pages Release Agreement
12/34/56
EX-10.2
from 10-Q 8 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Consulting Agreement
12/34/56
EX-10.1
from 10-Q 15 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Release Agreement
12/34/56
EX-10.17
from 10-K 8 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Consulting Agreement
12/34/56
EX-10.16
from 10-K 14 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Release Agreement
12/34/56
EX-10.14
from 10-K 8 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Consulting Agreement
12/34/56
EX-10.13
from 10-K 14 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Release Agreement
12/34/56
EX-10.11
from 10-K 25 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Employment Agreement
12/34/56
EX-10.10
from 10-K 25 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Employment Agreement
12/34/56
EX-10.5
from 10-K 16 pages Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan
12/34/56
EX-10.3
from 10-K 3 pages Zentalis Pharmaceuticals, Inc. Non-Employee Director Compensation Program Effective January 1, 2025
12/34/56
EX-10.1
from 10-Q 16 pages Material contract
12/34/56
EX-10.1
from 10-Q 16 pages Material contract
12/34/56
EX-10.24
from 10-K 20 pages Material contract
12/34/56
EX-10.23
from 10-K 21 pages Material contract
12/34/56
EX-10.20
from 10-K 6 pages Material contract
12/34/56
EX-10.19
from 10-K 7 pages Material contract
12/34/56
EX-10.18
from 10-K 18 pages Material contract
12/34/56
EX-10.16
from 10-K 7 pages Material contract
12/34/56